Circulating Neuregulin-1 and Chronic Heart Failure with Preserved Ejection

Chronic heart failure (CHF) with preserved ejection fraction (CHFpEF) is an unsolved, socially relevant challenge since it is associated with a high level of morbidity and mortality. Early markers for this pathology are unavailable, and therapeutic approaches are undeveloped. This necessitates extensive studying the mechanisms of CHFpEF to identify therapeutic targets. According to current notions, systemic inflammation and endothelial dysfunction play an important role in the pathogenesis of CHFpEF. These processes induce the development of myocardial fibrosis and impairment of cardiomyocyte relaxation, thereby resulting in diastolic dysfunction and increased left ventricular (LV) filling pressure. Neuregulin-1 (NRG-1) is a paracrine growth factor and a natural agonist of ErbB receptor family synthesized in the endothelium of coronary microvessels. The NRG-1 / ErbB4 system of the heart is activated at early stages of CHFpEF to enhance the cardiomyocyte resistance to oxidative stress. Preclinical and clinical (phases II and III) studies have shown that the recombinant NRG-1 therapy results in improvement of myocardial contractility and in LV reverse remodeling. Results of recent studies suggest possible anti-inflammatory and antifibrotic effects of NRG-1, which warrants studying the activity of this system in patients with CHFpEF.

1. Pfeffer MA, Shah AM, Borlaug BA. Heart Failure With Preserved Ejection Fraction In Perspective. Circulation Research. 2019;124(11):1598–617. DOI: 10.1161/CIRCRESAHA.119.313572

2. Fomin I.V. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;8:7–13. DOI: 10.15829/1560-4071-2016-8-7-13

3. Levy D. Echocardiographically Detected Left Ventricular Hypertrophy: Prevalence and Risk Factors: The Framingham Heart Study. Annals of Internal Medicine. 1988;108(1):7–13. DOI: 10.7326/0003- 4819-108-1-7

4. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A et al. Outcome of heart failure with preserved ejection fraction in a population-based study. The New England Journal of Medicine. 2006;355(3):260–9. DOI: 10.1056/NEJMoa051530

5. Forman D, Gaziano JM. Irbesartan in patients with heart failure and preserved ejection fraction. Current Cardiovascular Risk Reports. 2009;3(5):311–2. DOI: 10.1007/s12170-009-0056-1

6. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet. 2003;362(9386):777–81. DOI: 10.1016/S0140-6736(03)14285-7

7. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal. 2006;27(19):2338–45. DOI: 10.1093/eurheartj/ehl250

8. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2014;370(15):1383–92. DOI: 10.1056/NEJMoa1313731

9. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2019;381(17):1609–20. DOI: 10.1056/NEJMoa1908655

10. Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC: Cardiovascular Imaging. 2020;13(1):245–57. DOI: 10.1016/j.jcmg.2018.12.034

11. Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ, Bradshaw AD et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131(14):1247–59. DOI: 10.1161/CIRCULATIONAHA.114.013215

12. Ito H, Ishida M, Makino W, Goto Y, Ichikawa Y, Kitagawa K et al. Cardiovascular magnetic resonance feature tracking for characterization of patients with heart failure with preserved ejection fraction: correlation of global longitudinal strain with invasive diastolic functional indices. Journal of Cardiovascular Magnetic Resonance. 2020;22(1):42. DOI: 10.1186/s12968-020-00636-w

13. Giamouzis G, Schelbert EB, Butler J. Growing Evidence Linking Microvascular Dysfunction With Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association. 2016;5(2):e003259. DOI: 10.1161/JAHA.116.003259

14. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology. 2013;62(4):263–71. DOI: 10.1016/j.jacc.2013.02.092

15. Lam CSP, Lyass A, Kraigher-Krainer E, Massaro JM, Lee DS, Ho JE et al. Cardiac Dysfunction and Noncardiac Dysfunction as Precursors of Heart Failure With Reduced and Preserved Ejection Fraction in the Community. Circulation. 2011;124(1):24–30. DOI: 10.1161/ CIRCULATIONAHA.110.979203

16. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. Journal of the American College of Cardiology. 2012;59(11):998–1005. DOI: 10.1016/j.jacc.2011.11.040

17. Taube A, Schlich R, Sell H, Eckardt K, Eckel J. Inflammation and metabolic dysfunction: links to cardiovascular diseases. American Journal of Physiology-Heart and Circulatory Physiology. 2012;302(11):H2148–65. DOI: 10.1152/ajpheart.00907.2011

18. Jelic S, Lederer DJ, Adams T, Padeletti M, Colombo PC, Factor PH et al. Vascular Inflammation in Obesity and Sleep Apnea. Circulation. 2010;121(8):1014–21. DOI: 10.1161/CIRCULATIONAHA.109.900357

19. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM et al. Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection Fraction: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial. Circulation: Heart Failure. 2011;4(3):324–31. DOI: 10.1161/CIRCHEARTFAILURE.110.959890

20. Tian N, Moore RS, Braddy S, Rose RA, Gu J-W, Hughson MD et al. Interactions between oxidative stress and inflammation in salt-sensitive hypertension. American Journal of Physiology-Heart and Circulatory Physiology. 2007;293(6):H3388–95. DOI: 10.1152/ajpheart.00981.2007

21. Glezeva N, Voon V, Watson C, Horgan S, McDonald K, Ledwidge M et al. Exaggerated Inflammation and Monocytosis Associate With Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction: Evidence of M2 Macrophage Activation in Disease Pathogenesis. Journal of Cardiac Failure. 2015;21(2):167–77. DOI: 10.1016/j.cardfail.2014.11.004

22. Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circulation. Heart Failure. 2011;4(1):44–52. DOI: 10.1161/CIRCHEARTFAILURE.109.931451

23. Tarbit E, Singh I, Peart JN, Rose’Meyer RB. Biomarkers for the identification of cardiac fibroblast and myofibroblast cells. Heart Failure Reviews. 2019;24(1):1–15. DOI: 10.1007/s10741-018-9720-1

24. Krüger M, Kötter S, Grützner A, Lang P, Andresen C, Redfield MM et al. Protein Kinase G Modulates Human Myocardial Passive Stiffness by Phosphorylation of the Titin Springs. Circulation Research. 2009;104(1):87–94. DOI: 10.1161/CIRCRESAHA.108.184408

25. Meerson F.Z., Ugolev A.A. Abnormalities in transmembrane Ca2+ current in heart failure. Kardiologiia. 1980;20(1):68–75.

26. Runte KE, Bell SP, Selby DE, Häußler TN, Ashikaga T, LeWinter MM et al. Relaxation and the Role of Calcium in Isolated Contracting Myocardium From Patients With Hypertensive Heart Disease and Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure. 2017;10(8):e004311. DOI: 10.1161/CIRCHEARTFAILURE.117.004311

27. De Keulenaer GW, Feyen E, Dugaucquier L, Shakeri H, Shchendrygina A, Belenkov YN et al. Mechanisms of the Multitasking Endothelial Protein NRG-1 as a Compensatory Factor During Chronic Heart Failure. Circulation: Heart Failure. 2019;12(10):e006288. DOI: 10.1161/ CIRCHEARTFAILURE.119.006288

28. Ryzhov S, Matafonov A, Galindo CL, Zhang Q, Tran T-L, Lenihan DJ et al. ERBB signaling attenuates proinflammatory activation of nonclassical monocytes. American Journal of Physiology-Heart and Circulatory Physiology. 2017;312(5):H907–18. DOI: 10.1152/ajpheart.00486.2016

29. Liu W, Zscheppang K, Murray S, Nielsen HC, Dammann CEL. The ErbB4 receptor in fetal rat lung fibroblasts and epithelial type II cells. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2007;1772(7):737–47. DOI: 10.1016/j.bbadis.2007.04.008

30. Xu Z, Jiang J, Ford G, Ford BD. Neuregulin-1 is neuroprotective and attenuates inflammatory responses induced by ischemic stroke. Biochemical and Biophysical Research Communications. 2004;322(2):440–6. DOI: 10.1016/j.bbrc.2004.07.149

31. Galindo CL, Ryzhov S, Sawyer DB. Neuregulin as a Heart Failure Therapy and Mediator of Reverse Remodeling. Current Heart Failure Reports. 2014;11(1):40–9. DOI: 10.1007/s11897-013-0176-2

32. García-Rivello H, Taranda J, Said M, Cabeza-Meckert P, Vila-Petroff M, Scaglione J et al. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. American Journal of Physiology-Heart and Circulatory Physiology. 2005;289(3):H1153–60. DOI: 10.1152/ajpheart.00048.2005

33. Galindo CL, Kasasbeh E, Murphy A, Ryzhov S, Lenihan S, Ahmad FA et al. Anti‐Remodeling and Anti‐Fibrotic Effects of the Neuregulin‐1β Glial Growth Factor 2 in a Large Animal Model of Heart Failure. Journal of the American Heart Association. 2014;3(5):e000773. DOI: 10.1161/JAHA.113.000773

34. Bersell K, Arab S, Haring B, Kühn B. Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury. Cell. 2009;138(2):257–70. DOI: 10.1016/j.cell.2009.04.060

35. Gao R, Zhang J, Cheng L, Wu X, Dong W, Yang X et al. A Phase II, Randomized, Double-Blind, Multicenter, Based on Standard Therapy, Placebo-Controlled Study of the Efficacy and Safety of Recombinant Human Neuregulin-1 in Patients With Chronic Heart Failure. Journal of the American College of Cardiology. 2010;55(18):1907–14. DOI: 10.1016/j.jacc.2009.12.044

36. Jabbour A, Hayward CS, Keogh AM, Kotlyar E, McCrohon JA, England JF et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. European Journal of Heart Failure. 2011;13(1):83–92. DOI: 10.1093/eurjhf/ hfq152

37. Geisberg C, Wang G, Safa RN, Smith HM, Anderson B, Peng X-Y et al. Circulating neuregulin-1β levels vary according to the angiographic se- verity of coronary artery disease and ischemia: Coronary Artery Disease. 2011;22(8):577–82. DOI: 10.1097/MCA.0b013e32834d3346

38. Geisberg CA, Abdallah WM, da Silva M, Silverstein C, Smith HM, Abramson V et al. Circulating Neuregulin During the Transition From Stage A to Stage B/C Heart Failure in a Breast Cancer Cohort. Journal of Cardiac Failure. 2013;19(1):10–5. DOI: 10.1016/j.cardfail.2012.11.006

39. Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC et al. Neuregulin-1β Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure. Circulation. 2009;120(4):310–7. DOI: 10.1161/CIRCULATIONAHA.109.856310

40. Zeng Z, Gui C, Nong Q, Du F, Zhu L. Serum neuregulin-1β levels are positively correlated with VEGF and Angiopoietin-1 levels in patients with diabetes and unstable angina pectoris. International Journal of Cardiology. 2013;168(3):3077–9. DOI: 10.1016/j.ijcard.2013.04.088

41. Hage C, Wärdell E, Linde C, Donal E, Lam CSP, Daubert C et al. Circulating neuregulin1‐β in heart failure with preserved and reduced left ventricular ejection fraction. ESC Heart Failure. 2020;7(2):445–55. DOI: 10.1002/ehf2.12615

42. Russell KS, Stern DF, Polverini PJ, Bender JR. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. American Journal of Physiology-Heart and Circulatory Physiology. 1999;277(6):H2205–11. DOI: 10.1152/ajpheart.1999.277.6.H2205

43. Lemmens K, Segers VFM, Demolder M, De Keulenaer GW. Role of Neuregulin-1/ErbB2 Signaling in Endothelium-Cardiomyocyte Cross-talk. Journal of Biological Chemistry. 2006;281(28):19469–77. DOI: 10.1074/jbc.M600399200

44. Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K et al. Pentraxin 3 Is a New Inflammatory Marker Correlated With Left Ventricular Diastolic Dysfunction and Heart Failure With Normal Ejection Fraction. Journal of the American College of Cardiology. 2011;57(7):861–9. DOI: 10.1016/j.jacc.2010.10.018

45. Wisniacki N. Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart. 2005;91(1):32–7. DOI: 10.1136/hrt.2003.029652

46. Wu C-K, Lee J-K, Chiang F-T, Yang C-H, Huang S-W, Hwang J-J et al. Plasma levels of tumor necrosis factor-α and interleukin-6 are associated with diastolic heart failure through downregulation of sarcoplasmic reticulum Ca2+ ATPase: Critical Care Medicine. 2011;39(5):984–92. DOI: 10.1097/CCM.0b013e31820a91b9

47. Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? European Journal of Heart Failure. 2011;13(10):1087– 95. DOI: 10.1093/eurjhf/hfr079

48. Zach V, Bähr FL, Edelmann F. Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction. Cardiac Failure Review. 2020;6:1–7. DOI: 10.15420/cfr.2019.10

49. Okuyan E, Uslu A, Çakar MA, Sahin I, Önür I, Enhos A et al. Homocysteine Levels in Patients with Heart Failure with Preserved Ejection Fraction. Cardiology. 2010;117(1):21–7. DOI: 10.1159/000320106

50. Frantz S, Falcao-Pires I, Balligand J-L, Bauersachs J, Brutsaert D, Ciccarelli M et al. The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC: Immunity in chronic heart failure. European Journal of Heart Failure. 2018;20(3):445–59. DOI: 10.1002/ejhf.1138

51. Patel RB, Colangelo LA, Reiner AP, Gross MD, Jacobs DR, Launer LJ et al. Cellular Adhesion Molecules in Young Adulthood and Cardiac Function in Later Life. Journal of the American College of Cardiology. 2020;75(17):2156–65. DOI: 10.1016/j. jacc.2020.02.060

52. Leuschner F, Nahrendorf M. Novel functions of macrophages in the heart: insights into electrical conduction, stress, and diastolic dysfunction. European Heart Journal. 2020;41(9):989–94. DOI: 10.1093/eurheartj/ehz159

53. Zhang Y, Bauersachs J, Langer HF. Immune mechanisms in heart failure: Heart failure and immune mechanisms. European Journal of Heart Failure. 2017;19(11):1379–89. DOI: 10.1002/ejhf.942

54. Fujiu K, Nagai R. Contributions of cardiomyocyte–cardiac fibroblast– immune cell interactions in heart failure development. Basic Research in Cardiology. 2013;108(4):357. DOI: 10.1007/s00395-013-0357-x

55. van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. Journal of Leukocyte Biology. 2009;85(2):195–204. DOI: 10.1189/jlb.0708400

56. Riehle C, Bauersachs J. Key inflammatory mechanisms underlying heart failure. Herz. 2019;44(2):96–106. DOI: 10.1007/s00059-019-4785-8

57. Vermeulen Z, Hervent A-S, Dugaucquier L, Vandekerckhove L, Rombouts M, Beyens M et al. Inhibitory actions of the NRG-1/ErbB4 pathway in macrophages during tissue fibrosis in the heart, skin, and lung. American Journal of Physiology. Heart and Circulatory Physiology. 2017;313(5):H934–45. DOI: 10.1152/ajpheart.00206.2017

58. Schumacher MA, Hedl M, Abraham C, Bernard JK, Lozano PR, Hsieh JJ et al. ErbB4 signaling stimulates pro-inflammatory macrophage apoptosis and limits colonic inflammation. Cell Death & Disease. 2017;8(2):e2622–e2622. DOI: 10.1038/cddis.2017.42

59. Wu L, Walas S, Leung W, Sykes DB, Wu J, Lo EH et al. Neuregulin1-β Decreases IL-1β-Induced Neutrophil Adhesion to Human Brain Microvascular Endothelial Cells. Translational Stroke Research. 2015;6(2):116–24. DOI: 10.1007/s12975-014-0347-9

60. Duca F, Kammerlander AA, Zotter-Tufaro C, Aschauer S, Schwaiger ML, Marzluf BA et al. Interstitial Fibrosis, Functional Status, and Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From a Prospective Cardiac Magnetic Resonance Imaging Study. Circulation: Cardiovascular Imaging. 2016;9(12):e005277. DOI: 10.1161/CIRCIMAGING.116.005277

61. Kanagala P, Cheng ASH, Singh A, Khan JN, Gulsin GS, Patel P et al. Relationship Between Focal and Diffuse Fibrosis Assessed by CMR and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. JACC: Cardiovascular Imaging. 2019;12(11):2291–301. DOI: 10.1016/j.jcmg.2018.11.031

62. Kasner M, Westermann D, Lopez B, Gaub R, Escher F, Kühl U et al. Diastolic Tissue Doppler Indexes Correlate With the Degree of Collagen Expression and Cross-Linking in Heart Failure and Normal Ejection Fraction. Journal of the American College of Cardiology. 2011;57(8):977–85. DOI: 10.1016/j.jacc.2010.10.024

63. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction. Circulation. 2015;131(6):550–9. DOI: 10.1161/CIRCULATIONAHA.114.009625

64. Su M-YM, Lin L-Y, Tseng Y-HE, Chang C-C, Wu C-K, Lin J-L et al. CMR-Verified Diffuse Myocardial Fibrosis Is Associated With Diastolic Dysfunction in HFpEF. JACC: Cardiovascular Imaging. 2014;7(10):991–7. DOI: 10.1016/j.jcmg.2014.04.022

65. Rommel K-P, von Roeder M, Latuscynski K, Oberueck C, Blazek S, Fengler K et al. Extracellular Volume Fraction for Characterization of Patients With Heart Failure and Preserved Ejection Fraction. Journal of the American College of Cardiology. 2016;67(15):1815–25. DOI: 10.1016/j.jacc.2016.02.018

66. Mascherbauer J, Marzluf BA, Tufaro C, Pfaffenberger S, Graf A, Wexberg P et al. Cardiac Magnetic Resonance Postcontrast T1 Time Is Associated With Outcome in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Cardiovascular Imaging. 2013;6(6):1056–65. DOI: 10.1161/CIRCIMAGING.113.000633

67. Gupte M, Lal H, Ahmad F, Sawyer DB, Hill MF. Chronic Neuregulin1β Treatment Mitigates the Progression of Postmyocardial Infarction Heart Failure in the Setting of Type 1 Diabetes Mellitus by Suppressing Myocardial Apoptosis, Fibrosis, and Key Oxidant-Producing Enzymes. Journal of Cardiac Failure. 2017;23(12):887–99. DOI: 10.1016/j.cardfail.2017.08.456

68. LeWinter MM, Granzier H. Cardiac Titin: A Multifunctional Giant. Circulation. 2010;121(19):2137–45. DOI: 10.1161/CIRCULATIONAHA.109.860171

69. Fürst DO, Osborn M, Nave R, Weber K. The organization of titin filaments in the half-sarcomere revealed by monoclonal antibodies in immunoelectron microscopy: a map of ten nonrepetitive epitopes starting at the Z line extends close to the M line. Journal of Cell Biology. 1988;106(5):1563–72. DOI: 10.1083/jcb.106.5.1563

70. Trombitás K, Jin J-P, Granzier H. The Mechanically Active Domain of Titin in Cardiac Muscle. Circulation Research. 1995;77(4):856–61. DOI: 10.1161/01.RES.77.4.856

71. Trombitás K, Freiburg A, Centner T, Labeit S, Granzier H. Molecular Dissection of N2B Cardiac Titin’s Extensibility. Biophysical Journal. 1999;77(6):3189–96. DOI: 10.1016/S0006-3495(99)77149-3

72. Linke WA, Rudy DE, Centner T, Gautel M, Witt C, Labeit S et al. I-Band Titin in Cardiac Muscle Is a Three-Element Molecular Spring and Is Critical for Maintaining Thin Filament Structure. Journal of Cell Biology. 1999;146(3):631–44. DOI: 10.1083/jcb.146.3.631

73. Cazorla O, Freiburg A, Helmes M, Centner T, McNabb M, Wu Y et al. Differential Expression of Cardiac Titin Isoforms and Modulation of Cellular Stiffness. Circulation Research. 2000;86(1):59–67. DOI: 10.1161/01.RES.86.1.59

74. Borbély A, van der Velden J, Papp Z, Bronzwaer JGF, Edes I, Stienen GJM et al. Cardiomyocyte Stiffness in Diastolic Heart Failure. Circulation. 2005;111(6):774–81. DOI: 10.1161/01.CIR.0000155257.33485.6D

75. Borbély A, Falcao-Pires I, van Heerebeek L, Hamdani N, Édes I, Gavina C et al. Hypophosphorylation of the Stiff N2B Titin Isoform Raises Cardiomyocyte Resting Tension in Failing Human Myocardium. Circulation Research. 2009;104(6):780–6. DOI: 10.1161/CIRCRESAHA.108.193326

76. Hopf A-E, Andresen C, Kötter S, Isić M, Ulrich K, Sahin S et al. Diabetes-Induced Cardiomyocyte Passive Stiffening Is Caused by Impaired Insulin-Dependent Titin Modification and Can Be Modulated by Neuregulin-1. Circulation Research. 2018;123(3):342–55. DOI: 10.1161/CIRCRESAHA.117.312166

77. Adão R, Mendes-Ferreira P, Maia-Rocha C, Santos-Ribeiro D, Rodrigues PG, Vidal-Meireles A et al. Neuregulin-1 attenuates right ventricular diastolic stiffness in experimental pulmonary hypertension. Clinical and Experimental Pharmacology and Physiology. 2019;46(3):255–65. DOI: 10.1111/1440-1681.13043

78. Miao J, Huang S, Su YR, Lenneman CA, Wright M, Harrell FE et al. Effects of endogenous serum neuregulin-1β on morbidity and mortality in patients with heart failure and left ventricular systolic dysfunction. Biomarkers. 2018;23(7):704–8. DOI: 10.1080/1354750X.2018.1485054